Stock TARA PROTARA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Protara Therapeutics, Inc.

Equities

TARA

US74365U1079

Market Closed - Nasdaq
Other stock markets
 16:30:00 2024-05-03 EDT 		5-day change 1st Jan Change
2.91 USD +0.69% Intraday chart for Protara Therapeutics, Inc. -0.51% +55.19%
05-02 Protara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04-30 Protara Therapeutics, Inc. announced that it has received $44.998327 million in funding from a group of investors CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Protara Therapeutics: Q1 Earnings Snapshot
AQ
Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update
AQ
Protara Therapeutics Announces Oversubscribed $45 Million Private Placement Financing
AQ
Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition
AQ
Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC
AQ
Protara Therapeutics: Q4 Earnings Snapshot
AQ
Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
AQ
Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
AQ
Protara Therapeutics to Participate in Upcoming Investor Conferences
AQ
Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic Oncology
AQ
Protara Therapeutics: Q3 Earnings Snapshot
AQ
Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business Update
AQ
Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations
AQ
Non Muscle Invasive Bladder Cancer Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)
AQ
Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in Situ
AQ
Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
AQ
Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business Update
AQ
Protara Therapeutics Announces Dosing of First Patients in Phase 1b ADVANCED-1EXP Trial of TARA-002 in NMIBC Patients with Carcinoma in Situ
AQ
Protara Therapeutics: Q1 Earnings Snapshot
AQ
PROTARA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TARA Stock
  4. News Protara Therapeutics, Inc.
  5. Press Releases